Department of Neurosurgery, Wollongong Hospital, Wollongong, New South Wales, Australia.
J Clin Neurosci. 2012 Mar;19(3):370-4. doi: 10.1016/j.jocn.2011.07.025. Epub 2012 Jan 25.
Non-functioning pituitary adenomas are primarily a surgically managed pathology, but recurrence or regrowth is not uncommon. Previous large series have retrospectively validated the use of the Gamma Knife (GK) as an adjuvant treatment. To our knowledge, we present the largest case series to date with the Linear Accelerator (Linac) for the management of this pathology. In this study we review the clinical course of 118 patients, 51 of whom had stereotactic radiosurgery (SRS) and 67 who had fractionated stereotactic radiotherapy (FSRT); the discriminatory feature being proximity to the optic chiasm. For comparison purposes a population of 53 patients who had conventional radiotherapy (CRT) is included. The local control rates at 5 years for SRS, FRST and CRT were 100%, 93% and 87% respectively. Treatment-related morbidity was low. These data confirm that Linac SRS and FSRT are safe and effective for the treatment of non-functioning pituitary adenomas.
无功能垂体腺瘤主要是一种通过手术治疗的疾病,但复发或再生长并不罕见。以前的大型系列研究回顾性验证了伽玛刀(GK)作为辅助治疗的使用。据我们所知,我们目前提供了最大的病例系列,使用直线加速器(Linac)来治疗这种疾病。在这项研究中,我们回顾了 118 名患者的临床病程,其中 51 名患者接受了立体定向放射外科手术(SRS),67 名患者接受了分次立体定向放射治疗(FSRT);区分特征是靠近视交叉。为了比较目的,还包括了 53 名接受常规放射治疗(CRT)的患者。SRS、FSRT 和 CRT 的 5 年局部控制率分别为 100%、93%和 87%。治疗相关的发病率较低。这些数据证实,Linac SRS 和 FSRT 是治疗无功能垂体腺瘤的安全有效的方法。